Immuneering Corp
IMRX · XNASCIK 1790340fmd_1DCFF2TQW9HFCWF323G75BM3FXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 2 | 2 | 0 | 0 | – | – |
| Cost of revenue | 1 | 1 | 0 | 0 | – | – |
| Gross profit | 1 | 1 | 0 | 0 | – | – |
| Research and development | 15 | 27 | 36 | 42 | 48 | 42 |
| Total operating expenses | 18 | 35 | 52 | 58 | 64 | 59 |
| Operating income | (17) | (34) | (52) | (58) | (64) | (59) |
| Interest and investment income | 0 | 0 | 1 | 4 | 3 | 3 |
| Other non-operating income (expense) | – | (0) | 0 | 1 | 0 | 0 |
| Income before taxes | (17) | (34) | (51) | – | – | – |
| Income tax expense | – | (0) | – | – | – | 0 |
| Net income from continuing operations | – | (34) | – | – | – | – |
| Net income | (17) | (34) | (51) | (53) | (61) | (56) |